Translation Acceleration Grant

Translation Acceleration Grants


Prostate Cancer Canada (PCC) has invited applications for investigator-initiated Translation Acceleration Grants (TAG) that address a significant issue in the management of prostate cancer, with a high potential of preventing disease progression and/or improving quality of life in the short term.
 
Starting in 2014, each competition has addressed a significant issue in the management of prostate cancer. The intent of the program is not to support new discovery. Rather the grants should leverage existing knowledge and capabilities to accelerate impact without overlapping currently funded Prostate Cancer Canada and Movember foundation initiatives.

TAG1: Aggressive vs. indolent prostate cancer
TAG2: Novel therapeutics for aggressive disease
True Nth Survivorship Grants (TAG3)
TAG4: Innovative approaches to manage prostate cancer

These opportunities were awarded by Prostate Cancer Canada and proudly funded in part by the Movember Foundation.
smaller-still.jpg
See Funded Project Database for information on funded grants.




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
BRCA2 gene implicated in rare but lethal prostate cancer

January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer.
More

Scientists identify DNA signature linked to prostate cancer severity

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature.
More

Thank You to our Canadian Mo Bros and Sistas!

TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign.
More


Click here for news archive